XNCR (NASDAQ) - Xencor Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98401F1057
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California. Web URL: https://www.xencor.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for XNCR (NASDAQ) - Xencor Inc

Classification

Market Cap in USD 1,279m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2013-12-03

Ratings

Fundamental -5.62
Dividend -
Performance 5y -3.97
Rel. Performance vs Sector -2.93
Analysts 4.53
Fair Price Total Ret. 17.57
Fair Price DCF todo

Technical

Growth TTM -23.70%
CAGR 5y -12.21%
CAGR / Mean Drawdown 5y -0.39
Sharpe Ratio TTM -0.78
Alpha vs SP500 TTM -41.95
Beta vs SP500 5y weekly 0.93
CAPM 7.35%
Average Daily Range 2m 3.06%
Reversal Oscillator 31.23
Volatility GJR Garch 1y 40.10%
Price / SMA 50 -9.8%
Price / SMA 200 -25.01%
Current Volume 447.6k
Average Volume 20d 359.7k

Dividends

Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%